Key result
Cotreatment with eplerenone, candesartan, or tempol attenuated increased systolic blood pressure and vascular inflammatory changes in aldosterone-treated hypertensive rats.
Why the study?
Does cotreatment with eplerenone, candesartan, or tempol attenuate hypertension, vascular injury, and oxidative stress in aldosterone-treated hypertensive rats?
Population
Aldosterone-treated hypertensive rats
Comparison
Cotreatment with selective mineralocorticoid… vs Aldosterone treatment alone (implied control)
Design
Preclinical
Authors
Loading...
Hypothesis-generating for local RAS in aldosterone injury; leaves open clinical translation of combined MR/ARB blockade.
Does cotreatment with eplerenone, candesartan, or tempol attenuate hypertension, vascular injury, and oxidative stress in aldosterone-treated hypertensive rats?
Aldosterone induces hypertension, vascular inflammation, and oxidative stress through both Ang II-dependent (via vascular ACE upregulation) and Ang II-independent pathways.
Hirono et al. (2007) studied Aldosterone-induced hypertension. Eplerenone, candesartan, and tempol vs. Aldosterone alone was evaluated on Development of hypertension, vascular injury, oxidative stress, and inflammatory-related gene expression. Cotreatment with eplerenone, candesartan, or tempol attenuated increased systolic blood pressure and vascular inflammatory changes in aldosterone-treated hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: